Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16019508 | 0.78 | PTGS1 (0.32) | PTGS1PTGS2 | |
| SCHEMBL17761929 | 0.78 | S1PR1 (0.33) | PTGS1PTGS2 | |
| SCHEMBL6611601 | 0.73 | — | — | |
| SCHEMBL2612162 | 0.72 | — | — | |
| SCHEMBL104897 | 0.72 | GAA (0.50) | GAA | |
| SCHEMBL12824830 | 0.70 | PTGS1 (0.34) | PTGS1PTGS2 | |
| SCHEMBL11293798 | 0.70 | GAA (0.35) | GAA | |
| SCHEMBL22861185 | 0.70 | S1PR1 (0.33) | PTGS1PTGS2 | |
| SCHEMBL19422760 | 0.69 | — | — | |
| SCHEMBL17624098 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295145-A1 | PYRROLIDINE DERIVATIVES AND METHODS OF USE | GENENTECH INC (US) | 2023-09-21 | — | — | US | disclosed |
| US-20210315872-A1 | COMPOUNDS AND METHODS FOR EP300 or CBP MODULATION AND INDICATIONS THEREFOR | Opna Bio SA (CH) | 2021-10-14 | — | — | US | disclosed |
| US-20180127413-A1 | TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295145-A1 | PYRROLIDINE DERIVATIVES AND METHODS OF USE | DPYD, TP53, GLS | GAA 1211/4885PTGS1 309/4885PTGS2 265/4885 |
| US-20180127413-A1 | TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | TP53, TK2, TOP2A | GAA 280/4885PTGS1 1847/4885PTGS2 1732/4885 |
| US-20210315872-A1 | COMPOUNDS AND METHODS FOR EP300 or CBP MODULATION AND INDICATIONS THEREFOR | EP300, CREBBP, HDAC11 | GAA 4527/4885PTGS1 3061/4885PTGS2 4110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.